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neous outbreaks of a new and then a mysterious virus named Ebola
(Fig. 1) in the Sudan and what was then Zaire, now known as the Dem-
ocratic Republic of Congo. Since then, sporadic outbreaks caused by
Ebola virus have resulted in approximately 2387 cases and 1590 deaths
(http://www.who.int/mediacentre/factsheets/fs103/en/). This year,
Ebola virus returned to the center stage as the Western African coun-
tries of Guinea, Liberia, and Sierra Leone are facing an unprecedented
and uncontrolled outbreak caused by a new Zaire ebolavirus strain that
has been linked by epidemiological evidence to a potential “patient
zero” who succumbed to infection in December, 2013 (Baize et al.,
2014). The number of cases in this outbreak has surpassed that for all
previously reported Ebola virus outbreaks combined. As of September
18, 2014, there have been more than 5347 cases with 2630 deaths;
these numbers include 318 infected healthcare workers, half of
whom have died (http://www.cdc.gov/vhf/ebola/outbreaks/guinea/
index.html). In past outbreaks, the case fatality rates have varied from
25% to 90% (http://www.who.int/mediacentre/factsheets/fs103/en/);
the case fatality rate of the current outbreak is 53% (http://
www.cdc.gov/vhf/ebola/outbreaks/guinea/index.html.). However, due
to limited access to Ebola treatment units and the stigma associated
with this disease, many infections may have gone unreported, so the
true number of infected people is most likely much higher, and the
true case fatality rate will not be known until the outbreak is over.
The early symptoms of Ebola virus hemorrhagic fever disease are
non-speciﬁc: fever, malaise, muscle pain, diarrhea, and vomiting. Even-
tually, recognizable hemorrhagic symptoms are evident including
vomiting of blood, nosebleeds, and a characteristic rash, late in the
course of the disease, in roughly half of those infected (http://
www.who.int/mediacentre/factsheets/fs103/en/). Transmission occurs
through direct contact with virus-contaminated body ﬂuids (blood,
secretions, or other bodily ﬂuids), materials such as bedding con-
taminated with these ﬂuids, through the handling and preparation of
contaminated food such as bushmeat, or through direct or indirect con-
tact with infected bats, a potential animal reservoir for Ebola virus
(http://www.who.int/mediacentre/factsheets/fs103/en/; Leroy et al.,
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licensed vaccines and antiviral therapeutics to treat Ebola virus-
infected patients. However, considerable progress has been made in
more recent years, and the current outbreak has fuelled major efforts
to evaluate candidate therapeutics in clinical trials.
Supportive care that includes largely oral rehydrationwith solutions
containing electrolytes is the typical course of treatment for Ebola-
infected patients. Currently, several experimental Ebola virus vaccines
confer varying degrees of protective efﬁcacy in animal models. An
ideal Ebola virus vaccine would elicit strong and protective responses
after a single immunization and have therapeutic beneﬁts. One of the
most extensively tested Ebola virus vaccine platforms is based on a
replication-competent vesicular stomatitis virus (VSV) expressing
Ebola virus glycoprotein(s) (the major viral immunogen). A single
dose of 107 recombinant VSV particles has been shown to be effective
against Ebola, and its close relative Marburg virus, in prophylactic and
post-exposure situations in nonhuman primate models (review; Marzi
et al., 2011). The use of replication-competent vaccine viruses always
raises safety concerns; however, such concernswill be addressed in cur-
rent and future clinical trials.
Another vaccine platform is based on a replication-defective,
chimpanzee adenovirus vector, ChAd3. One study showed that the vac-
cination of nonhuman primates with a single dose of 1010 recombinant
adenovirus particles expressing the glycoproteins of Z. ebolavirus con-
ferred complete protection from a lethal challenge with Z. ebolavirus,
whereas a lower vaccine dosage protected most infected animals
(Stanely et al., 2014). Given the success of this vaccine platform in non-
human primates, ChAd3 has now entered a Phase I clinical trial to test
its safety, tolerability, and immunogenicity in human volunteers.
In addition to these and other experimental vaccine platforms,
monoclonal antibody therapy has been developed for therapeutic use.
In particular, a cocktail of three monoclonal antibodies against the
Z. ebolavirus glycoprotein, called ZMapp (developed by Mapp Biophar-
maceutical Inc.), provided complete protection in infected nonhuman
primates that were already showing signs of Ebola virus disease
(i.e., at ﬁve days post-challenge) (Qiu et al., 2014). This success in non-
human primates prompted the US Food and Drug Administration to ap-
prove ZMapp for compassionate use in patients infected with Ebola
virus during the current outbreak. Although ﬁve patients treated with
ZMapp survived their Ebola virus infection, at least two individuals
have died from the infection despite receiving the antibody cocktail.
Hence, the effectiveness of ZMapp against Ebola virus infection inthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Scanning electronmicrograph of cells infectedwith Ebola virus. Numerous ﬁlamentous virions can be seen being released from the cells. Courtesy of Dr. Takeshi Noda, International
Research Center for Infectious Diseases, Institute of Medicine Science, University of Tokyo.
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contained in the ZMapp cocktail are produced in tobacco plants, and
current stocks of ZMapp have been exhausted.
The development of antiviral drugs against Ebola virus has also
progressed. The nucleoside analogs BCX4430 and T-705 (favipiravir)
inhibit viral RNA synthesis with a minimal effect on cellular RNA syn-
thesis (Warren et al., 2014; Oestereich et al., 2014). Studies have dem-
onstrated the efﬁcacy of T-705 against Ebola virus in a rodent model
(Oestereich et al., 2014), and of BXC4430 against Marburg virus in a
nonhuman primate model (Warren et al., 2014). Moreover, both com-
pounds also inhibit other medically important, human RNA viruses
(Warren et al., 2014; Oestereich et al., 2014). In particular, T-705 is ap-
proved in Japan to combat pandemic inﬂuenza. In addition, small mole-
cule therapeutics that include lipid nanoparticle/small interfering RNA
technology have been successful in treatment against Ebola virus in
nonhuman primates (Geisbert et al., 2010) and have entered clinical
trials. Hence, these compounds hold promise as candidates to treat or
prevent Ebola infection.
Since the ﬁrst Ebola outbreak, we have furthered our understanding
of this virus and its life cycle, and advances have been made in the de-
velopment of potential prophylactic and therapeutic treatments. How-
ever, we are not there yet, and more basic and translational research
is needed. But limited funding has slowed the progress. Additional
funding for basic research is essential to identify the virus reservoir,
determine the pathogenesis, and identify viral and host targets for anti-
viral drugdiscovery. Similarly,more funding for translational research is
needed to test novel vaccines and antiviral drugs in nonhuman primates
(the gold-standard animal model in Ebola virus research) and to test
promising candidates in clinical trials.
The current outbreak is a glaringwake-up call of the devastation the
Ebola virus can inﬂict on the human population. This outbreak hasexposed the world's lack of preparedness to respond to and control
such infectious disease outbreaks. Our society has concerned itself
with the potential of biological terrorist attacks or laboratory-acquired
outbreaks; while such scenarios cannot be dismissed, this Ebola virus
outbreak makes plain that the true threat of infectious diseases comes
from nature. Funding and research (including gain-of-function experi-
ments)must be stable and steady, not dictated by theworld's attention,
to ensure that we are ready for the next crisis.
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